A number of recent events have brought renewed scrutiny to the pharmaceutical industry, threatening fines and increased regulation. This posting explores these events and perhaps a more balanced view of responsibility for the opioid epidemic. The posting also provides an overview of President Trump’s recent proposal to curb drug industry prices.